Background: Ascites is the most common complication of liver cirrhosis and about 5-10% of all cases develop
refractory ascites, 50% of such patients die within 6 months of its development. Aim of the Work: to assess the usefulness of
adding midodrine beside the standard medical treatment for patients with liver cirrhosis and refractory ascites. Patients and
Methods: This study included 78 patients with liver cirrhosis and refractory ascites or recurrent ascites, Group A: (n=37)
patients on standard medical treatment (SMT) [low sodium diet + diuretic therapy (loop diuretic in a dose 40-160 mg/day and
distal acting diuretic in a dose 100-400 mg/day + large volume paracentesis as needed] Group B: (n=41) patients with standard
medical treatment (SMT) and midodrine tolerable dose. Results: Statistical significant difference between the SMT group and
midodrine group as regard reduction in body weight and increase in mean arterial blood pressure and 24 h-urinary volume
where P value was < 0.05. Conclusion, midodrine is a safe treatment for patients with liver cirrhosis and its addition to
standard medical treatment is associated with better control of ascites.